(NASDAQ: PSTX) Poseida Therapeutics's forecast annual revenue growth rate of -6.3% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Poseida Therapeutics's revenue in 2024 is $64,703,000.On average, 2 Wall Street analysts forecast PSTX's revenue for 2024 to be $4,342,010,715, with the lowest PSTX revenue forecast at $2,894,673,810, and the highest PSTX revenue forecast at $5,789,347,620. On average, 2 Wall Street analysts forecast PSTX's revenue for 2025 to be $1,929,782,540, with the lowest PSTX revenue forecast at $964,891,270, and the highest PSTX revenue forecast at $2,894,673,810.
In 2027, PSTX is forecast to generate $7,382,383,107 in revenue, with the lowest revenue forecast at $7,382,383,107 and the highest revenue forecast at $7,382,383,107.